Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era-Reference-Cited by-同舟云学术

Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era

Published:2021-04-27 Issue:4 Volume:39 Page:490-497
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Guan Qingpei¹,Hong Yuheng¹,Hu Ge¹,Zhou Qiqi¹,Li Lanfang¹,Qian Zhengzi¹,Zhou Shiyong¹,Ren Xiubao²,Qiu Lihua¹,Wang Xianhuo¹^ORCID,Zhang Huilai¹

Affiliation:

1. Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino‐US Center for Lymphoma and Leukemia Research Tianjin China

2. Departments of Immunology/Biotherapy Tianjin Medical University Cancer Institute and Hospital Tianjin China

Funder

Natural Science Foundation of Tianjin City

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2869

Reference25 articles.

1. Non-Hodgkin's lymphoma.Involvement of Waldeyer's ring